Egetis Therapeutics AB (LTS:0ABW) Payments of Debt: kr-29.70 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABW Egetis Therapeutics AB LTS:0ABW
61 GF Score
Price kr6.64
GF Value kr5.64
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Payments of Debt?

Egetis Therapeutics AB LTS:0ABW 61 Payments of Debt is kr-29.70 Mil as of Mar. 2026. GuruFocus rates LTS:0ABW with a GF Score™ of 61/100 and a GF Value™ of kr5.64 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Egetis Therapeutics AB's Payments of Debt for the three months ended in Mar. 2026 was kr-7.50 Mil.

Egetis Therapeutics AB's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was kr-29.70 Mil.

Egetis Therapeutics AB Payments of Debt Related Terms

Egetis Therapeutics AB Payments of Debt Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Payments of Debt Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.50 -7.50 -3.00 -7.70 -29.30

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.00 -7.10 -7.50 -7.60 -7.50
LTS:0ABW
61GF Score
Egetis Therapeutics AB LTS:0ABW
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-29.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of kr-29.70 Mil mean?
Egetis Therapeutics AB (LTS:0ABW) has a Payments of Debt of kr-29.70 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Payments of Debt too high?
Egetis Therapeutics AB's current Payments of Debt is kr-29.70 Mil. Overall, Egetis Therapeutics AB has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Payments of Debt compare to VRTX and REGN?
Egetis Therapeutics AB's Payments of Debt of kr-29.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Payments of Debt is kr-29.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.64, compared to a current price of kr6.64 — trading 17.7% above its estimated fair value. The current Payments of Debt is kr-29.70 Mil. Egetis Therapeutics AB's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Payments of Debt is kr-29.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.64 is trading 17.7% above its estimated GF Value™ of kr5.64. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for LTS:0ABW:

  • Payments of Debt: kr-29.70 Mil
  • GF Value™: kr5.64 vs. price of kr6.64 (17.7% above fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
61GF Score

Get the complete analysis for LTS:0ABW

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.64
Price
kr5.64
GF Value